Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinomas obtained from patients treated with trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Triulzi, Tiziana, De Cecco, Loris, Sandri, Marco, Prat, Aleix, Giussani, Marta, Paolini, Biagio, Carcangiu, Marialuisa L., Canevari, Silvana, Bottini, Alberto, Balsari, Andrea, Menard, Sylvie, Generali, Daniele, Campiglio, Manuela, Di Cosimo, Serena, Tagliabue, Elda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695052/
https://www.ncbi.nlm.nih.gov/pubmed/26334217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695052/
https://www.ncbi.nlm.nih.gov/pubmed/26334217

Ejemplares similares